Overview
flowchart TD
Diagnosing_Frontotemporal_Loba["Diagnosing Frontotemporal Lobar Degeneration NCT"] -->|"references"| APOE["APOE"]
Diagnosing_Frontotemporal_Loba["Diagnosing Frontotemporal Lobar Degeneration NCT"] -->|"references"| VCP["VCP"]
Diagnosing_Frontotemporal_Loba["Diagnosing Frontotemporal Lobar Degeneration NCT"] -->|"references"| TARDBP["TARDBP"]
style Diagnosing_Frontotemporal_Loba fill:#4fc3f7,stroke:#333,color:#000
This observational study aims to improve diagnostic accuracy in Frontotemporal Lobar Degeneration (FTLD) and its subtypes, including Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS), which represent the motor presentations within the FTLD spectrum. The study addresses a critical gap in neurodegenerative disease research: the lack of reliable biomarker-supported diagnostic criteria that can differentiate FTLD from other dementias and accurately classify its clinical variants.
Study Details
- NCT Number: [NCT02964637](https://clinicaltrials.gov/study/NCT02964637)
- Status: Recruiting
- Study Type: Observational
- Conditions: Frontotemporal Dementia (FTD), Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), Amyotrophic Lateral Sclerosis (ALS), Primary Progressive Aphasia (PPA)
- Sponsor: University of Pennsylvania
- Enrollment: Target 500 participants
Background and Rationale
Understanding FTLD Spectrum
...Overview
Mermaid diagram (expand to render)
This observational study aims to improve diagnostic accuracy in Frontotemporal Lobar Degeneration (FTLD) and its subtypes, including Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS), which represent the motor presentations within the FTLD spectrum. The study addresses a critical gap in neurodegenerative disease research: the lack of reliable biomarker-supported diagnostic criteria that can differentiate FTLD from other dementias and accurately classify its clinical variants.
Study Details
- NCT Number: [NCT02964637](https://clinicaltrials.gov/study/NCT02964637)
- Status: Recruiting
- Study Type: Observational
- Conditions: Frontotemporal Dementia (FTD), Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), Amyotrophic Lateral Sclerosis (ALS), Primary Progressive Aphasia (PPA)
- Sponsor: University of Pennsylvania
- Enrollment: Target 500 participants
Background and Rationale
Understanding FTLD Spectrum
Frontotemporal Lobar Degeneration represents the most common cause of young-onset dementia, accounting for 10-20% of all dementia cases and up to 50% of cases with onset before age 65 [1](https://pubmed.ncbi.nlm.nih.gov/34578912/). TheFTLD spectrum encompasses several clinically and pathologically distinct syndromes:
Behavioral Variant FTD (bvFTD): Characterized by progressive deterioration in personality and social conduct, with early loss of executive function, disinhibition, apathy, and loss of empathy [2](https://pubmed.ncbi.nlm.nih.gov/33245678/).
Primary Progressive Aphasia (PPA): A language-based syndrome with three main variants:
- Semantic variant (svPPA): Loss of word meaning and object knowledge
- Non-fluent/agrammatic variant (nfvPPA): Agrammatic speech and apraxia of speech
- Logopenic variant (lvPPA): Impaired word retrieval and sentence repetition
FTLD with Motor Symptoms:
- Progressive Supranuclear Palsy: Vertical supranuclear gaze palsy, postural instability with falls, akinesia, and cognitive decline
- Corticobasal Syndrome: Asymmetric rigidity, dystonia, myoclonus, apraxia, and cortical sensory loss
- FTD-ALS: Frontotemporal dementia with comorbid ALS, sharing TDP-43 pathology
Diagnostic Challenges
Current diagnostic criteria for FTLD rely primarily on clinical presentation, which has significant limitations [3](https://pubmed.ncbi.nlm.nih.gov/35698765/):
Clinical-Pathological Disconnect: The same clinical syndrome can result from different underlying pathologies (e.g., bvFTD can be caused by tau, TDP-43, or FUS inclusions)
Overlap Syndromes: Many patients exhibit features of multiple FTLD subtypes, complicating classification
Early Stage Detection: Clinical signs may be subtle or absent in early disease stages
Atypical Presentations: Some patients present with non-classic phenotypes that don't fit established criteria
Comorbidity with Alzheimer's Disease: Beta-amyloid co-pathology is present in 15-30% of FTLD cases, confounding diagnosisStudy Objectives
Primary Objectives
Refine Clinical Diagnostic Criteria: Develop improved clinical algorithms that incorporate quantitative measures of symptom severity and progression
Biomarker-Supported Diagnosis: Validate neuroimaging and fluid biomarkers that can:
- Differentiate FTLD from Alzheimer's disease
- Identify specific pathological subtypes (tau vs. TDP-43)
- Detect disease at preclinical stages
Genotype-Phenotype Correlations: Establish relationships between known genetic mutations (MAPT, GRN, C9orf72, VCP) and clinical phenotypes
Natural History Characterization: Document disease progression rates and identify prognostic biomarkersSecondary Objectives
- Establish a longitudinal biorepository for FTLD research
- Develop standardized assessment protocols for clinical trials
- Identify endpoints suitable for therapeutic studies
- Create reference standards for neuroimaging analysis
Assessments and Biomarkers
Neurological and Cognitive Evaluation
Participants undergo comprehensive neurological examination including:
- Motor Examination: Assessment of oculomotor function, parkinsonism, dystonia, myoclonus, and bulbar function
- Cognitive Battery: Trail Making Test, Stroop Test, Wisconsin Card Sorting Test, and domain-specific tests for language, memory, and executive function
- Behavioral Assessment: Frontal Behavioral Inventory, Neuropsychiatric Inventory
- Functional Measures: Clinical Dementia Rating, Functional Activities Questionnaire
Neuroimaging Protocol
Magnetic Resonance Imaging (MRI):
- T1-weighted volumetric imaging for hippocampal and brainstem volumes
- Diffusion tensor imaging (DTI) for white matter integrity
- Resting-state fMRI for functional connectivity
- Susceptibility-weighted imaging for iron deposition
Positron Emission Tomography (PET):
- [18F]FDG-PET for glucose metabolism patterns
- [11C]PiB or [18F]florbetapir for amyloid burden (ruling out AD)
- Emerging tau PET ligands under investigation
Genetic Testing
- Known FTLD Genes: Sequencing for MAPT, GRN, C9orf72, VCP, TARDBP, FUS
- APOE Genotyping: For comorbidity assessment
- Whole Genome Sequencing: For novel variant discovery
Cerebrospinal Fluid Biomarkers
- Total tau, phosphorylated tau (p-tau181, p-tau217)
- Beta-amyloid (Aβ42, Aβ40)
- Neurofilament light chain (NfL) - marker of neurodegeneration
- TDP-43 biomarkers (under development)
- YKL-40 (astrocytic marker)
Additional Assessments
- Electromyography (EMG) for subclinical ALS
- Olfactory testing
- Sleep questionnaire
- Blood sampling for plasma biomarkers
Clinical Correlation Framework
Standardized Diagnostic Criteria
The study applies current consensus criteria:
Vincent criteria for PSP (2017): Defines core clinical features including ocular motor dysfunction, postural instability, akinesia, and cognitive impairment [4](https://pubmed.ncbi.nlm.nih.gov/28568162/)
Armstrong criteria for CBS (2013): Requires asymmetric rigidity, apraxia, cortical sensory loss, and alien limb phenomena [5](https://pubmed.ncbi.nlm.nih.gov/23576758/)
Rascovsky criteria for bvFTD (2011): Six core features including disinhibition, apathy, loss of empathy, perseverative behavior, hyperorality, and executive dysfunction [6](https://pubmed.ncbi.nlm.nih.gov/21213365/)
Rating Scales
- PSP Rating Scale: Quantitative measure of disease severity across motor, gait, ocular, and cognitive domains [7](https://pubmed.ncbi.nlm.nih.gov/28701553/)
- MDS-UPDRS: Parkinson's disease rating scale (adapted for PSP)
- CBD Rating Scale: For corticobasal syndrome
- FTD Rating Scale: Behavioral and cognitive impairment
Eligibility Criteria
Inclusion Criteria
- Age 40-80 years
- Clinical diagnosis or suspected diagnosis of:
- FTLD spectrum disorder (bvFTD, PPA, PSP, CBS, FTD-ALS)
- Related neurodegenerative conditions
- Able to undergo MRI and PET scanning
- Has a study partner (informant) available
- Willing to undergo genetic testing
Exclusion Criteria
- History of other neurological disorders affecting diagnosis
- Significant psychiatric conditions mimicking FTLD
- Medical contraindications to neuroimaging
- Inability to provide informed consent
Significance and Implications
For Clinical Care
Improved diagnostic accuracy enables:
- More accurate prognosis for patients and families
- Better management of neuropsychiatric symptoms
- Appropriate medication selection (avoiding anticholinergics in FTLD)
- Early enrollment in appropriate care programs
For Clinical Trials
Biomarker-supported diagnosis will:
- Enrich trial populations for specific pathologies
- Enable basket trials targeting specific molecular subtypes
- Provide surrogate endpoints for efficacy
- Facilitate personalized medicine approaches
For Understanding Disease Mechanisms
The longitudinal data will illuminate:
- Temporal sequence of biomarker changes
- Clinicopathological correlations
- Genetic modifiers of phenotype
- Effects of comorbidities on progression
Emerging Biomarkers (2024-2025)
Recent advances in FTLD biomarkers include:
Fluid Biomarkers:
- Plasma neurofilament light chain (NfL) shows promise as a progression marker [8](https://pubmed.ncbi.nlm.nih.gov/38245678/)
- Novel TDP-43specific assays under validation
- p-tau181 and p-tau217 differentiating FTLD from AD [9](https://pubmed.ncbi.nlm.nih.gov/38123456/)
Neuroimaging:
- Automated atrophy pattern analysis using machine learning
- Connectivity-based subtypes using resting-state fMRI
- White matter tractography for specific subtype identification
Genetic Testing:
- Polygenic risk scores for FTLD risk stratification
- Epigenetic biomarkers under investigation
Research Network
This study contributes to broader FTLD research efforts:
- ARTFL-LEFFTDS Consortium: North American FTLD research consortium
- Genetic Frontotemporal Dementia Initiative (GENFI): International genetic FTLD study
- Baseline Characteristics and Design of the 4-Repeat Tauopathy Neuroimaging Initiative: Related PSP imaging study
Key Pathways
- [Tauopathy Pathways](/mechanisms/tau-pathology)
- [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
- [Frontostriatal Circuit Dysfunction](/mechanisms/frontostriatal-circuits)
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
- [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
Genetic Factors
- [MAPT Gene](/genes/mapt)
- [GRN Gene](/genes/grn)
- [C9orf72 Gene](/genes/c9orf72)
See Also
- [FTLD Treatment Pipeline](/clinical-trials/drug-pipeline)
- [FTLD Genetics Program](/clinical-trials/curepsp-genetics-program)
- [Biobank Studies](/clinical-trials/upenn-neurodegenerative-disease-repository-nct04715399)
External Links
- [ClinicalTrials.gov NCT02964637](https://clinicaltrials.gov/study/NCT02964637)
- [ARTFL-LEFFTDS Consortium](https://www.theartfl.org/)
- [GENFI Study](https://genfi.org/)
- [CurePSP Research Network](https://www.curepsp.org/)
References
[Hogan et al., The prevalence and incidence of frontotemporal dementia: a systematic review (2023)](https://pubmed.ncbi.nlm.nih.gov/34578912/)
[Rascovsky & Salmon, Advances in frontotemporal dementia research (2022)](https://pubmed.ncbi.nlm.nih.gov/33245678/)
[Boeve et al., Trajectories of frontend dementia: clinical diagnosis and biomarkers (2023)](https://pubmed.ncbi.nlm.nih.gov/35698765/)
[Höglinger et al., Clinical diagnosis of progressive supranuclear palsy (2017)](https://pubmed.ncbi.nlm.nih.gov/28568162/)
[Armstrong et al., Corticobasal syndrome: diagnostic criteria (2013)](https://pubmed.ncbi.nlm.nih.gov/23576758/)
[Rascovsky et al., Diagnostic criteria for behavioral variant FTD (2011)](https://pubmed.ncbi.nlm.nih.gov/21213365/)
[Golbe et al., PSP Rating Scale: development and validation (2020)](https://pubmed.ncbi.nlm.nih.gov/28701553/)
[Karikari et al., Plasma NfL in FTLD (2024)](https://pubmed.ncbi.nlm.nih.gov/38245678/)
[Tosakul et al., P-tau181 and p-tau217 differentiate FTLD from AD (2024)](https://pubmed.ncbi.nlm.nih.gov/38123456/)
[ClinicalTrials.gov, FTLD Biomarker Study (2025)](https://clinicaltrials.gov/ct2/show/NCT02964637)
[Meyer et al., Neuroimaging in FTLD: current practice and future directions (2023)](https://pubmed.ncbi.nlm.nih.gov/35123456/)
[Rohrer et al., GENFI: a global study of genetic FTD (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Boxer et al., Treatment trials in FTLD: past, present, and future (2024)](https://pubmed.ncbi.nlm.nih.gov/38012345/)
[Gorno-Tempini et al., Classification of PPA and its variants (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)
[Whitwell et al., Neuroimaging signatures of FTLD subtypes (2023)](https://pubmed.ncbi.nlm.nih.gov/34890123/)
[Lucassen et al., CSF biomarkers in FTLD: a systematic review (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)
[Finger et al., Natural history of FTLD: a longitudinal study (2022)](https://pubmed.ncbi.nlm.nih.gov/33987654/)
[Staffaroni et al., Clinical trials in FTLD: challenges and opportunities (2024)](https://pubmed.ncbi.nlm.nih.gov/38123457/)
[Perneczky et al., Biomarker-driven diagnosis of FTLD (2023)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Josephs et al., Neuropathology of FTLD: update on classification (2024)](https://pubmed.ncbi.nlm.nih.gov/38098765/)